WO2023236971A1 - Cd73抗体鸡尾酒疗法 - Google Patents
Cd73抗体鸡尾酒疗法 Download PDFInfo
- Publication number
- WO2023236971A1 WO2023236971A1 PCT/CN2023/098753 CN2023098753W WO2023236971A1 WO 2023236971 A1 WO2023236971 A1 WO 2023236971A1 CN 2023098753 W CN2023098753 W CN 2023098753W WO 2023236971 A1 WO2023236971 A1 WO 2023236971A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- antigen
- binding protein
- pharmaceutical composition
- amino acid
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Definitions
- This application relates to the field of biomedicine, specifically to a CD73 antibody cocktail therapy.
- CD73 also known as NT5E, is an extracellular 5-nuclease (NT5E) with a molecular weight of approximately 70Kd. It is anchored to the cell surface through glycophosphatidylinositol (GPI) and mainly exists in the form of a dimer. Under normal physiological conditions, CD73 can be expressed in a variety of tissues or organs, such as liver, large intestine, kidney, spleen, lung, ovary, lymph node and other tissues.
- GPI glycophosphatidylinositol
- CD73 is abnormally highly expressed on the surface of a variety of tumor cells, including brain glioma, breast cancer, melanoma, non-small cell lung cancer, bladder cancer, ovarian cancer, colorectal cancer, etc., and clinical data show High expression of CD73 is closely related to poor prognosis of tumor patients, so CD73 can be used as a potential target for clinical treatment and prognosis of various tumors.
- the present application provides a pharmaceutical combination, which includes a first antigen-binding protein that specifically binds to CD73, and a second antigen-binding protein that specifically binds to CD73.
- the first antigen-binding protein and the second antigen-binding protein have Different CD73 antigen binding epitopes.
- the pharmaceutical combination described in this application has one or more of the following properties: (1) can specifically bind to CD73 protein; (2) has a high affinity with CD73 protein; (3) can inhibit the growth of tumor cells and/or proliferation.
- the first antigen binding protein and the second antigen binding protein bind to CD73 protein in a non-competitive manner.
- the first antigen binding protein and the second antigen binding protein are present in a mixture.
- the first antigen binding protein comprises at least one CDR in the antibody heavy chain variable region VH, which VH comprises the amino acid sequence set forth in SEQ ID NO: 8.
- the first antigen binding protein comprises HCDR3, which comprises the amino acid sequence set forth in SEQ ID NO: 1.
- the first antigen-binding protein comprises HCDR2, which comprises the amino acid sequence set forth in SEQ ID NO:2.
- the first antigen-binding protein includes HCDR1, which includes the amino acid sequence set forth in SEQ ID NO: 3.
- the first antigen binding protein comprises VH, and the VH comprises the amino acid sequence set forth in SEQ ID NO:8.
- the first antigen binding protein comprises an antibody heavy chain constant region.
- the antibody heavy chain constant region is derived from an IgG heavy chain constant region.
- the antibody heavy chain constant region is derived from a human IgG heavy chain constant region.
- the antibody heavy chain constant region comprises the amino acid sequence set forth in SEQ ID NO: 9.
- the first antigen binding protein comprises an antibody heavy chain comprising the amino acid sequence set forth in SEQ ID NO: 10.
- the first antigen binding protein comprises at least one CDR in the antibody light chain variable region VL, which VL comprises the amino acid sequence set forth in SEQ ID NO: 18.
- the first antigen-binding protein includes LCDR3, which includes the amino acid sequence set forth in SEQ ID NO: 11.
- the first antigen-binding protein comprises LCDR2 comprising the amino acid sequence set forth in SEQ ID NO: 12 (WAS).
- the first antigen-binding protein includes LCDR1, which includes the amino acid sequence set forth in SEQ ID NO: 13.
- the first antigen binding protein comprises a VL comprising the amino acid sequence set forth in SEQ ID NO: 18.
- the first antigen binding protein comprises an antibody light chain constant region.
- the antibody light chain constant region is derived from a human Ig ⁇ constant region.
- the antibody light chain constant region comprises the amino acid sequence set forth in SEQ ID NO: 19.
- the first antigen binding protein comprises an antibody light chain comprising the amino acid sequence set forth in SEQ ID NO: 20.
- the second antigen binding protein comprises at least one CDR in the antibody heavy chain variable region VH, which VH comprises the amino acid sequence set forth in SEQ ID NO: 27.
- the second antigen binding protein comprises HCDR3, which comprises the amino acid sequence set forth in SEQ ID NO: 21.
- the second antigen binding protein comprises HCDR2 comprising SEQ ID NO: The amino acid sequence shown in 22.
- the second antigen-binding protein includes HCDR1, which includes the amino acid sequence set forth in SEQ ID NO: 23.
- the second antigen binding protein comprises VH, and the VH comprises the amino acid sequence set forth in SEQ ID NO: 27.
- the second antigen binding protein comprises an antibody heavy chain constant region.
- the antibody heavy chain constant region is derived from an IgG heavy chain constant region.
- the antibody heavy chain constant region is derived from a human IgG heavy chain constant region.
- the antibody heavy chain constant region of the second antigen binding protein comprises the amino acid sequence shown in SEQ ID NO: 9.
- the second antigen binding protein comprises an antibody heavy chain comprising the amino acid sequence set forth in SEQ ID NO: 28.
- the second antigen binding protein comprises at least one CDR in the antibody light chain variable region VL, which VL comprises the amino acid sequence set forth in SEQ ID NO: 35.
- the second antigen binding protein includes LCDR3, which includes the amino acid sequence set forth in SEQ ID NO: 29.
- the second antigen binding protein comprises LCDR2 comprising the amino acid sequence set forth in SEQ ID NO: 30 (LAS).
- the second antigen-binding protein includes LCDR1, which includes the amino acid sequence set forth in SEQ ID NO: 31.
- the second antigen binding protein comprises a VL comprising the amino acid sequence set forth in SEQ ID NO: 35.
- the second antigen binding protein comprises an antibody light chain constant region.
- the antibody light chain constant region is derived from a human Ig ⁇ constant region.
- the antibody light chain constant region comprises the amino acid sequence set forth in SEQ ID NO: 19.
- the second antigen binding protein comprises an antibody light chain comprising the amino acid sequence set forth in SEQ ID NO: 36.
- the mass ratio of the first antigen-binding protein to the second antigen-binding protein in the pharmaceutical combination is about 1:5 to 5:1.
- the relationship between the first antigen-binding protein and the second antigen-binding protein in the pharmaceutical combination is The mass ratio is about 1:5.
- the mass ratio of the first antigen-binding protein to the second antigen-binding protein in the pharmaceutical combination is about 1:2.5.
- the mass ratio of the first antigen-binding protein to the second antigen-binding protein in the pharmaceutical combination is about 1:1.
- the mass ratio of the first antigen-binding protein to the second antigen-binding protein in the pharmaceutical combination is about 2.5:1.
- the mass ratio of the first antigen-binding protein to the second antigen-binding protein in the pharmaceutical combination is about 5:1.
- the present application also provides a pharmaceutical composition comprising the pharmaceutical combination, and optionally one or more pharmaceutically acceptable carriers.
- the concentration of the pharmaceutical combination is about 3-300 mg/mL.
- the concentration of the pharmaceutical combination is about 3-150 mg/mL.
- the concentration of the pharmaceutical combination is about 5-100 mg/mL.
- the concentration of the pharmaceutical combination is about 10-100 mg/mL.
- the concentration of the pharmaceutical combination is about 10-50 mg/mL.
- the concentration of the pharmaceutical combination is 30 ⁇ 5 mg/mL.
- the concentration of the pharmaceutical combination is 30 ⁇ 3 mg/mL.
- the pharmaceutically acceptable carrier includes a buffer.
- the buffer comprises an acidic buffer.
- the buffer comprises a neutral buffer.
- the buffer is selected from the group consisting of: acetate-acetate buffer, histidine-histidine hydrochloride buffer, citrate-citrate buffer, phosphate buffer solution, histidine-acetate buffer, tris-hydrochloride buffer, phosphate-citrate, or combinations thereof.
- the buffer is selected from the group consisting of acetate-acetic acid, citrate-citrate, histidine-histidine hydrochloride, phosphate, Tris-hydrochloride, Histidine-acetate, phosphate-citrate, or combinations thereof.
- the buffer is selected from the group consisting of sodium acetate-acetic acid, sodium citrate-citric acid, histidine-histidine hydrochloride, sodium dihydrogen phosphate-disodium hydrogen phosphate, Tris-hydrochloride, histidine-acetate, and phosphate-sodium citrate.
- the buffer has a concentration of about 5-100 mM.
- the buffer has a concentration of about 5-60 mM.
- the buffer has a concentration of about 5-50 mM.
- the buffer has a concentration of about 10-40 mM.
- the concentration of the buffer is 20 ⁇ 5mM.
- the concentration of the buffer is 20 ⁇ 2mM.
- the pharmaceutical composition has a pH of about 5-7.
- the pharmaceutical composition has a pH of about 6 ⁇ 0.5.
- the pharmaceutical composition has a pH of about 6 ⁇ 0.3.
- the pharmaceutical composition has a pH of about 6 ⁇ 0.1.
- the pharmaceutical composition has a pH of about 6.5 ⁇ 0.3.
- the pharmaceutical composition has a pH of about 7 ⁇ 0.3.
- the pharmaceutically acceptable carrier includes a stabilizer.
- the stabilizer is selected from the group consisting of sodium chloride, amino acids, sugar alcohols, or combinations thereof.
- the amino acid is selected from the group consisting of: proline, arginine, glycine, histidine, lysine, methionine Methionine, or combinations thereof.
- the sugar alcohol is selected from the group consisting of Sucrose, Mannitol, Trehalose, Sorbitol, or a combination thereof.
- the stabilizer is selected from the group consisting of sucrose, trehalose, sorbitol, mannitol, proline/sucrose, methionine/trehalose, glycine/mannitol, sodium chloride/sucrose, alcohol acid/sucrose, and lysine/trehalose.
- the stabilizer is present in an amount of about 0.15 wt.% to 20 wt.%.
- the stabilizer is present in an amount of about 0.15 wt.% to 10 wt.%.
- the stabilizer is present in an amount of about 0.15 wt.% to 8 wt.%.
- the stabilizer is present in an amount of about 4 ⁇ 1 wt.% or 8 ⁇ 1 wt.%.
- the stabilizer is present in an amount of about 4 ⁇ 0.5 wt.% or 8 ⁇ 0.5 wt.%.
- the stabilizer is present in an amount of about 4 wt.%, 5 wt.%, 7 wt.%, or 8 wt.%.
- the stabilizer is present in an amount of about 8 wt.%.
- the pharmaceutically acceptable carrier includes a surfactant.
- the surfactant is selected from the group consisting of polyoxyethylene sorbitan fatty acid esters, polyoxyethylene hydrogenated castor oil, glyceryl fatty acid esters, polysorbates, poloxamer, or its combination.
- the polysorbate is selected from the group consisting of polysorbate 20 (PS-20, Tween-20), polysorbate Sorbitan 40 (PS-40), polysorbate 60 (PS-60), polysorbate 80 (PS-80).
- the surfactant is selected from the group consisting of PS-20 (Tween-20) and PS-80 (Tween-80).
- the concentration of surfactant is about 0.001%-0.5%.
- the concentration of surfactant is about 0.005%-0.1%.
- the concentration of surfactant is about 0.005%, 0.01%, 0.03%, 0.05%, or 0.1%.
- the concentration of surfactant is about 0.01%.
- the concentration of surfactant is about 0.03%.
- the pharmaceutically acceptable carrier is selected from the group consisting of: (1) 20mM histidine-acetic acid, 8wt.% sucrose, 0.03wt.% Tween-80; (2) 20mM acetic acid Sodium-acetic acid, 8wt.% trehalose, 0.03wt.% Tween-80; (3) 20mM histidine-acetic acid, 1.5wt.% proline, 5wt.% sucrose, 0.03wt.% Tween-80 ; (4) 20mM sodium acetate-acetic acid, 0.15wt.% methionine, 8wt.% trehalose, 0.03wt.% Tween-80; (5) 20mM histidine-acetic acid, 8wt.% sucrose, 0.01wt.% Tween-80; (6) 20mM sodium acetate-acetic acid, 8wt.% trehalose, 0.01wt.% Tween-80; (7) 20mM histidine-acetic acid, 8
- the application provides said pharmaceutical combination and/or the use of said pharmaceutical composition in the preparation of a medicament for the prevention and/or treatment of diseases and/or conditions.
- the diseases and/or conditions include CD73-mediated diseases and/or conditions.
- the disease and/or disorder includes tumors.
- the tumors include solid tumors and/or hematological tumors.
- the disease and/or disorder is selected from the group consisting of pancreatic cancer, breast cancer, and idiopathic pulmonary fibrosis (IPF).
- pancreatic cancer breast cancer
- IPF idiopathic pulmonary fibrosis
- the breast cancer includes triple negative breast cancer.
- the present application also provides the pharmaceutical combination and/or the use of the pharmaceutical composition in preparing a detection kit for detecting the presence and/or content of CD73 protein.
- Figure 1 shows the effect of the cocktail antibody therapy described in this application on inhibiting CD73 enzyme activity.
- Figure 2 shows the binding affinity curves and response values of 900698 and 900725 to human CD73 protein under different loading conditions.
- Figure 3 shows the anti-tumor effect of anti-CD73 cocktail antibody in pancreatic cancer animal models.
- Figure 4 shows the anti-tumor effect of anti-CD73 cocktail antibody in triple-negative breast cancer animal model.
- Figure 5 shows a schematic diagram of the dosage regimen of the idiopathic pulmonary fibrosis (IPF) mouse model.
- IPF idiopathic pulmonary fibrosis
- Figure 6 shows the body weight of mice in each group of the idiopathic pulmonary fibrosis (IPF) mouse model.
- IPF idiopathic pulmonary fibrosis
- Figure 7 shows the results of mouse airway hyperresponsiveness detection (Penh change rate-Mch concentration curve).
- Figure 8 shows the classification histogram of the total number of inflammatory-related cells and the number of lymphocytes in the alveolar lavage fluid.
- Figure 9 shows the pathological scoring results of idiopathic pulmonary fibrosis.
- Figure 10 shows representative pictures of pathological sections of lung tissue resulting from pathological scoring in the experiment.
- each active ingredient/therapeutic agent can be each prepared as a separate formulation (solid, liquid, gel, etc.).
- each active ingredient/therapeutic agent can be present in different containers, It can also be formulated into the desired formulation with suitable carriers simultaneously or separately when necessary; in some embodiments, each active ingredient/therapeutic agent can be from different sources; in some embodiments, each active ingredient/therapeutic agent can Exists in the form of a mixture.
- CD73 is also referred to as “NT5E", “cluster of differentiation 73", “5'-nucleotidase (5'-NT)” or “extracellular 5'-nucleotidase”.
- the term encompasses "full-length”, unprocessed CD73 as well as any form of CD73 resulting from cellular processing.
- CD73 includes full-length wild-type CD73 and its mutants, fragments, variants, isoforms and homologs.
- the CD73 can include human CD73.
- the sequence for human CD73 can be found under Uniprot accession number P21589.
- the term "antigen-binding protein” generally refers to a protein with antigen-binding ability obtained from the natural state through artificial means.
- the "antigen binding protein” may comprise a moiety that binds an antigen and, optionally, a framework or framework portion that allows the antigen binding moiety to adopt a conformation that promotes binding of the antigen by the antigen binding moiety.
- the antigen-binding protein may comprise, for example, antibody-derived protein framework regions (FR) or alternative protein framework regions with grafted CDRs or CDR derivatives or artificial framework regions.
- Such frameworks include, but are not limited to, antibody-derived framework regions containing mutations introduced, eg, to stabilize the three-dimensional structure of the antigen-binding protein, as well as fully synthetic framework regions containing, eg, biocompatible polymers. See, for example, Korndorfer et al., 2003, Proteins: Structure, Function, and Bioinformatics, 53(1):121-129 (2003); Roque et al., Biotechnol. Prog. 20:639-654 (2004).
- antigen-binding proteins include, but are not limited to: human antibodies, humanized antibodies; chimeric antibodies; recombinant antibodies; single chain antibodies; bifunctional antibodies; trifunctional antibodies; tetrafunctional antibodies; Fab, Fab', Fv fragment, F (ab') 2 , F(ab) 2 , scFv, di-scFv, dAb, IgD antibody; IgE antibody; IgM antibody; IgG1 antibody; IgG2 antibody; IgG3 antibody; or IgG4 antibody and fragments thereof.
- variable domain and “variable region” are used interchangeably and generally refer to a portion of an antibody heavy chain and/or light chain.
- the variable domains of the heavy and light chains may be referred to as “ VH “ and “ VL “, respectively (or “VH” and “VL”, respectively). These domains are typically the most variable parts of the antibody (relative to other antibodies of the same type) and contain the antigen-binding site.
- variable generally refers to certain segments of the variable domains that may differ significantly in sequence between antibodies.
- the variable domains mediate antigen binding and determine the specificity of a given antibody for its particular antigen.
- variability is not evenly distributed across the entire variable domain. It is usually concentrated in three segments called hypervariable regions (CDRs or HVRs) in the light and heavy chain variable domains.
- CDRs or HVRs hypervariable regions
- the more highly conserved portion of the variable domain is called the framework region (FR).
- FR framework region
- the variable domains of native heavy and light chains each contain four FR regions, most adopting a ⁇ -sheet configuration, connected by three CDRs, which form a circular link and in some cases form part of the ⁇ -sheet structure .
- the CDRs in each chain are held in close proximity by the FR region, and the CDRs from the other chain together contribute to the formation of the antibody's antigen-binding site (see Kabat et al, Sequences of Immunological Interest, Fifth Edition, National Institute of Health, Bethesda, Md. (1991)).
- antibody generally refers to an immunoglobulin or fragment thereof or derivative thereof, encompassing any polypeptide including an antigen-binding site, whether produced in vitro or in vivo.
- the term includes, but is not limited to, polyclonal, monoclonal, monospecific, multispecific, nonspecific, humanized, single chain, chimeric, synthetic, recombinant, hybrid , mutated and transplanted antibodies.
- the term “antibody” also includes antibody fragments, such as Fab, F(ab') 2 , Fv, scFv, Fd, dAbs and other antibody fragments that retain antigen-binding functionality (e.g., specifically bind CLDN18.2). Typically, such a fragment should When including an antigen-binding domain.
- the basic 4-chain antibody unit is a heterotetrameric glycoprotein composed of two identical light (L) chains and two identical heavy (H) chains.
- IgM antibodies are composed of 5 basic heterotetramer units and another polypeptide called J chain, and contain 10 antigen-binding sites, while IgA antibodies include 2-5 that can combine with the J chain and polymerize to form a multivalent Combined basic 4-chain unit.
- a 4-chain unit is typically about 150,000 daltons.
- Each L chain is connected to the H chain by a covalent disulfide bond, while the two H chains are connected to each other by one or more disulfide bonds depending on the H chain isotype.
- Each H and L chain also has regularly spaced intrachain disulfide bridges.
- Each H chain has a variable domain (VH) at the N-terminus, followed by three constant domains (CH) for each of the ⁇ and ⁇ chains, and four CH domains for the ⁇ and ⁇ isoforms.
- Each L chain has a variable domain (VL) at the N-terminus and a constant domain at its other end. VL corresponds to VH, and CL corresponds to the first constant domain (CH1) of the heavy chain. Specific amino acid residues are thought to form the interface between the light and heavy chain variable domains. VH and VL pair together to form a single antigen binding site.
- Immunoglobulins can be divided into different classes or isotypes based on the amino acid sequence of the heavy chain (CH) constant domain. There are currently five classes of immunoglobulins: IgA, IgD, IgE, IgG, and IgM, with heavy chains named alpha, delta, epsilon, gamma, and mu, respectively.
- the gamma and alpha classes are further divided into subclasses based on relatively small differences in CH sequence and function, for example, humans express the following subclasses: IgG1, IgG2A, IgG2B, IgG3, IgG4, IgA1 and IgK1.
- CDR also known as “complementarity determining region” generally refers to a region in an antibody variable domain whose sequence is highly variable and/or forms a structurally defined loop.
- an antibody may include six CDRs; three in VH (HCDR1, HCDR2, HCDR3), and three in VL (LCDR1, LCDR2, LCDR3).
- naturally occurring camelid antibodies consisting solely of heavy chains function normally and stably in the absence of light chains. See, e.g., Hamers-Casterman et al., Nature 363:446-448 (1993); Sheriff et al, Nature Struct. Biol. 3:733-736 (1996).
- variable domains of the native heavy and/or light chains each contain four FR regions, i.e., four in the VH (H-FR1, H-FR2, H-FR3, and H-FR4), and/or Four in VL (L-FR1, L-FR2, L-FR3, and L-FR4).
- the term "antigen-binding fragment” generally refers to one or more fragments that have the ability to specifically bind an antigen.
- the antigen-binding fragment may include Fab, Fab', F(ab) 2 , Fv fragment, F(ab') 2 , scFv, di-scFv and/or dAb.
- Fab generally refers to the antigen-binding fragment of an antibody.
- papaya protein can be used Enzymes digest intact antibodies.
- the antibody is digested by papain to produce two identical antigen-binding fragments, the "Fab” fragment, and the residual "Fc” fragment (i.e., Fc region, same as above).
- the Fab fragment may consist of a complete L chain and the variable region of a heavy chain and the first constant region ( CH 1 ) of the H chain (V H ).
- Fab' fragment generally refers to a monovalent antigen-binding fragment of a human monoclonal antibody that is slightly larger than a Fab fragment.
- a Fab' fragment may include all of the light chain, all of the heavy chain variable region, and all or part of the first and second constant regions of the heavy chain.
- a Fab' fragment may also include part or all of the 220-330 amino acid residues of the heavy chain.
- F(ab')2 generally refers to antibody fragments produced by pepsin digestion of intact antibodies.
- the F(ab')2 fragment contains two Fab fragments held together by disulfide bonds and part of the hinge region.
- F(ab')2 fragments have bivalent antigen-binding activity and are capable of cross-linking antigens.
- Fv fragment generally refers to a monovalent antigen-binding fragment of a human monoclonal antibody, including all or part of the heavy chain variable region and the light chain variable region, and lacking the heavy chain constant region and the light chain constant region.
- Heavy chain variable regions and light chain variable regions include, for example, CDRs.
- an Fv fragment includes all or part of the approximately 110 amino acid amino-terminal variable regions of the heavy and light chains.
- the term "scFv” generally refers to a fusion protein comprising at least one antibody fragment comprising a variable region of a light chain and at least one antibody fragment comprising a variable region of a heavy chain, wherein the light and heavy chains are variable
- the regions are contiguous (eg via a synthetic linker such as a short flexible polypeptide linker) and can be expressed as a single chain polypeptide, and wherein the scFv retains the specificity of the intact antibody from which it is derived.
- a scFv may have the VL and VH variable regions described in any order (eg, relative to the N-terminus and C-terminus of the polypeptide), and the scFv may include VL-linker-VH Or VH-joint-VL can be included.
- the term “dAb” generally refers to an antigen-binding fragment having a VH domain, a VL domain, or a VH domain or a VL domain, see for example Ward et al. (Nature, 1989 Oct 12;341(6242):544-6) , refer to Holt et al., Trends Biotechnol., 2003, 21(11): 484-490; and refer to other published patent applications such as WO 06/030220, WO 06/003388 and Domantis Ltd.
- the term "monoclonal antibody” generally refers to a preparation of antibody molecules composed of a single molecule. Monoclonal antibodies are usually highly specific for a single antigenic site. Furthermore, unlike conventional polyclonal antibody preparations, which typically have different antibodies directed against different determinants, each monoclonal antibody is directed against a single determinant on the antigen. In addition to their specificity, the advantage of monoclonal antibodies is that they can be synthesized by hybridoma culture without contamination from other immunoglobulins.
- the modifier "monoclonal” indicates the characteristics of an antibody obtained from a substantially homogeneous population of antibodies and is not to be construed as requiring that the antibody be produced by any particular method. For example, monoclonal antibodies used in the present application can be prepared in hybridoma cells, or can be prepared by recombinant DNA methods.
- chimeric antibody generally refers to an antibody in which the variable regions are derived from one species and the constant regions are derived from another species.
- the variable regions are derived from an antibody from a laboratory animal, such as a rodent (a "parent antibody”), and the constant regions are derived from a human antibody, such that the resulting chimeric antibody is more effective in a human individual than the parent (eg, mouse-derived) antibody. Less likely to trigger an adverse immune response.
- humanized antibody generally refers to an antibody in which some or all of the amino acids outside the CDR region of a non-human antibody (eg, a mouse antibody) are replaced with corresponding amino acids derived from human immunoglobulins. Small additions, deletions, insertions, substitutions or modifications of amino acids in the CDR regions may also be allowed as long as they retain the ability of the antibody to bind a specific antigen.
- the humanized antibody may optionally comprise at least a portion of a human immunoglobulin constant region. "Humanized antibodies” retain antigen specificity similar to the original antibody.
- “Humanized” forms of non-human (eg, murine) antibodies may minimally comprise chimeric antibodies derived from sequences derived from non-human immunoglobulins.
- CDR region residues in a human immunoglobulin can be used with a non-human species (donor antibody) having the desired properties, affinity, and/or ability (such as mouse, rat , rabbit or non-human primate) CDR region residue substitution.
- donor antibody non-human species
- FR region residues of a human immunoglobulin can be replaced with corresponding non-human residues.
- humanized antibodies may contain amino acid modifications that are not present in the recipient antibody or in the donor antibody. These modifications may be made to further improve the performance of the antibody, such as binding affinity.
- Fully human antibody generally refers to an antibody that contains only human immunoglobulin protein sequences.
- a fully human antibody may contain murine glycans if it is produced in mice, in mouse cells, or in hybridomas derived from mouse cells.
- mouse antibody or “rat antibody” refers to an antibody comprising only mouse or rat immunoglobulin sequences, respectively.
- Fully human antibodies can be produced in humans and in transgenic animals with human immunoglobulin germline sequences by phage display or other molecular biology methods. Exemplary techniques that can be used to make antibodies are described in US Patents: 6,150,584, 6,458,592, 6,420,140. Other techniques, such as the use of libraries, are known in the art.
- the term “directly connected” is contrasted with the term “indirectly connected,” which generally refers to a direct connection.
- the direct connection may be a case where substances are directly connected without a spacer.
- the spacer may be a linker.
- the linker may be a peptide linker.
- the term “indirectly connected” generally refers to situations where substances are not directly connected.
- the indirect connection may be a connection through a spacer.
- the C-terminus of the L-FR1 and the N-terminus of the LCDR1 can be directly or indirectly connected.
- the term "pharmaceutical composition” generally refers to a composition for the prevention/treatment of a disease or condition.
- the pharmaceutical composition may contain one or more active ingredients, and optionally a pharmaceutically acceptable carrier.
- the pharmaceutical composition may further comprise one or more (pharmaceutically effective) carriers, stabilizers, excipients, diluents, solubilizers, surfactants, emulsifiers and/or preservatives. preparations. Acceptable ingredients of the composition at the doses and concentrations used Preferably it is non-toxic to the recipient.
- Pharmaceutical compositions of the invention include, but are not limited to, liquid, frozen and lyophilized compositions.
- the term "pharmaceutically acceptable carrier” generally includes pharmaceutically acceptable carriers, excipients, and/or stabilizers which, at the doses and concentrations employed, are harmful to the cells or cells to which they are exposed. Animals are non-venomous.
- Physiologically acceptable carriers may include, for example, buffers, antioxidants, low molecular weight (less than about 10 residues) polypeptides, proteins, hydrophilic polymers, amino acids, monosaccharides, disaccharides and other carbohydrates, chelating agents, Sugar alcohols, salt-forming counterions such as sodium; and/or nonionic surfactants.
- the term "subject” generally refers to a human or non-human animal including, but not limited to, a cat, dog, horse, pig, cow, sheep, rabbit, mouse, rat, or monkey.
- tumor generally refers to a neoplasm or solid lesion formed by abnormal cell growth.
- a tumor may be a solid tumor or a non-solid tumor.
- proteins, polypeptides and/or amino acid sequences involved should also be understood to include at least the following range: variants or homologues that have the same or similar functions as the protein or polypeptide.
- the variant may be, for example, one or more substitutions, deletions or additions in the amino acid sequence of the protein and/or the polypeptide (eg, an antibody specifically binding to CD73 or a fragment thereof) Amino acids in proteins or peptides.
- the functional variant may comprise one that has been replaced by at least 1, such as 1-30, 1-20 or 1-10, such as 1, 2, 3, 4 or 5 amino acids. , deletion and/or insertion of proteins or polypeptides with amino acid changes.
- the functional variant may substantially retain the biological properties of the protein or polypeptide prior to the alteration (eg, substitution, deletion, or addition).
- the functional variant may retain at least 60%, 70%, 80%, 90%, or 100% of the biological activity (eg, antigen-binding ability) of the protein or polypeptide prior to the alteration.
- the substitutions may be conservative substitutions.
- the homolog may be one that shares at least about 85% (e.g., has at least about 85%) the amino acid sequence of the protein and/or the polypeptide (e.g., an antibody that specifically binds CD73 or a fragment thereof). %, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99% or higher) sequence homology protein or peptide.
- homology generally refers to similarity, similarity or association between two or more sequences.
- Perfect sequence homology can be calculated by comparing the two sequences to be aligned in the comparison window and determining the presence of identical nucleic acid bases (for example, A, T, C, G, I) in the two sequences.
- FASTA and BLAST A description of the FASTA algorithm can be found in WR Pearson and DJ Lipman, "Improved Tools for Biological Sequence Comparison," Proc. Natl. Acad. Sci., 85: 2444-2448, 1988; and DJ Lipman and WRPearson, "Fast and Sensitive Protein Similarity Search," Science, 227: 1435-1441, 1989.
- a description of the BLAST algorithm can be found in "A basic local alignment search tool" by S. Altschul, W. Gish, W. Miller, EW Myers, and D. Lipman, Journal of Molecular Biology, 215: 403-410, 1990.
- the term “comprises” generally means including, encompassing, containing or encompassing. In some cases, it also means “for” or “composed of”.
- the term "about” generally refers to a variation within the range of 0.5% to 10% above or below the specified value, such as 0.5%, 1%, 1.5%, 2%, 2.5%, above or below the specified value. 3%, 3.5%, 4%, 4.5%, 5%, 5.5%, 6%, 6.5%, 7%, 7.5%, 8%, 8.5%, 9%, 9.5%, or 10%.
- the present application provides a pharmaceutical combination comprising a first antigen-binding protein that specifically binds to CD73, and a second antigen-binding protein that specifically binds to CD73.
- the first antigen-binding protein has one or more of the following properties:
- the first antigen binding protein and the second antigen binding protein may have different CD73 antigen binding epitopes.
- the first antigen-binding protein and the second antigen-binding protein can bind to the CD73 protein in a non-competitive manner.
- the first antigen-binding protein may exist in a mixture with the second antigen-binding protein.
- the first antigen-binding protein and the second antigen-binding protein can be present in the same container and mixed.
- the first antigen-binding protein may comprise at least one CDR in the variable region VH of the antibody heavy chain, so The VH may comprise the amino acid sequence shown in SEQ ID NO:8.
- the first antigen-binding protein may comprise HCDR3, and the HCDR3 may comprise the amino acid sequence shown in SEQ ID NO: 1.
- the first antigen-binding protein may comprise HCDR2, and the HCDR2 may comprise the amino acid sequence shown in SEQ ID NO: 2.
- the first antigen-binding protein may comprise HCDR1, and the HCDR1 may comprise the amino acid sequence shown in SEQ ID NO:3.
- the first antigen-binding protein may include HCDR1, HCDR2 and HCDR3, the HCDR1 may include the amino acid sequence shown in SEQ ID NO:3, and the HCDR2 may include the amino acid sequence shown in SEQ ID NO:2 sequence, and the HCDR3 may comprise the amino acid sequence shown in SEQ ID NO:1.
- the first antigen-binding protein may comprise H-FR1
- the C-terminus of the H-FR1 is directly or indirectly connected to the N-terminus of the HCDR1
- the H-FR1 may comprise SEQ ID NO: The amino acid sequence shown in 4.
- the first antigen-binding protein may comprise H-FR2, the H-FR2 is located between the HCDR1 and the HCDR2, and the H-FR2 may comprise SEQ ID NO: 5. Amino acid sequence.
- the first antigen-binding protein may comprise H-FR3, the H-FR3 is located between the HCDR2 and the HCDR3, and the H-FR3 may comprise SEQ ID NO: 6 Amino acid sequence.
- the first antigen-binding protein may comprise H-FR4, the N-terminus of the H-FR4 is directly or indirectly connected to the C-terminus of the H-FR3, and the H-FR4 comprises SEQ ID NO. :The amino acid sequence shown in 7.
- the first antigen-binding protein may comprise H-FR1, H-FR2, H-FR3 and H-FR4.
- the H-FR1 includes the amino acid sequence shown in SEQ ID NO:4 or SEQ ID NO:24
- the H-FR2 may include the amino acid sequence shown in SEQ ID NO:5 or SEQ ID NO:25
- the H-FR3 may include the amino acid sequence shown in SEQ ID NO:6 or SEQ ID NO:26
- the H-FR4 may include the amino acid sequence shown in SEQ ID NO:7.
- the first antigen-binding protein includes VH, and the VH includes the amino acid sequence shown in SEQ ID NO:8.
- the first antigen binding protein may comprise an antibody heavy chain constant region.
- the antibody heavy chain constant region is derived from an IgG heavy chain constant region.
- the antibody heavy chain constant region is derived from a human IgG heavy chain constant region.
- the antibody heavy chain constant region is derived from a human IgG1 heavy chain constant region or a human IgG4 heavy chain constant region.
- the antibody heavy chain constant region includes the amino acid sequence shown in SEQ ID NO: 9.
- the first antigen-binding protein may comprise an antibody heavy chain, and the antibody heavy chain may comprise the amino acid sequence shown in SEQ ID NO: 10.
- the first antigen-binding protein may comprise at least one CDR in the antibody light chain variable region VL, which may comprise the amino acid sequence shown in SEQ ID NO: 18.
- the first antigen-binding protein may comprise LCDR3, and the LCDR3 may comprise the amino acid sequence shown in SEQ ID NO: 11.
- the first antigen-binding protein may comprise LCDR2, and the LCDR2 may comprise the amino acid sequence shown in SEQ ID NO: 12 (WAS).
- the first antigen-binding protein may comprise LCDR1, and the LCDR1 may comprise the amino acid sequence shown in SEQ ID NO: 13.
- the first antigen-binding protein may include LCDR1, LCDR2 and LCDR3.
- the LCDR1 may include the amino acid sequence described in SEQ ID NO:13
- the LCDR2 may include the amino acid sequence described in SEQ ID NO:12 (WAS).
- the amino acid sequence shown is, and the LCDR3 may comprise the amino acid sequence shown in SEQ ID NO: 11.
- the first antigen-binding protein may comprise L-FR1
- the C-terminus of the L-FR1 is directly or indirectly connected to the N-terminus of the LCDR1
- the L-FR1 may comprise SEQ ID NO: The amino acid sequence shown in 14.
- the first antigen-binding protein may comprise L-FR2, the L-FR2 is located between the LCDR1 and the LCDR2, and the L-FR2 may comprise SEQ ID NO:15 Amino acid sequence.
- the first antigen-binding protein may comprise L-FR3, the L-FR3 is located between the LCDR2 and the LCDR3, and the L-FR3 comprises the amino acid shown in SEQ ID NO: 16 sequence.
- the first antigen-binding protein may comprise L-FR4, the N-terminus of the L-FR4 is directly or indirectly connected to the C-terminus of the L-FR3, and the L-FR4 comprises SEQ ID NO. :The amino acid sequence shown in 17.
- the first antigen-binding protein may comprise L-FR1, L-FR2, L-FR3 and L-FR4.
- the L-FR1 may include the amino acid sequence shown in SEQ ID NO:14
- the L-FR2 may include the amino acid sequence shown in SEQ ID NO:15
- the L-FR3 may include SEQ ID NO:16
- the L-FR4 may include the amino acid sequence shown in SEQ ID NO:17.
- the first antigen-binding protein includes VL, and the VL includes the amino acid sequence shown in SEQ ID NO: 18.
- the first antigen binding protein may comprise an antibody light chain constant region.
- the antibody light chain constant region may be derived from a human Ig ⁇ constant region.
- the antibody light chain constant region may comprise the amino acid sequence shown in SEQ ID NO: 19.
- the first antigen-binding protein may comprise an antibody light chain, and the antibody light chain may comprise the amino acid sequence shown in SEQ ID NO: 20.
- the first antigen-binding protein may comprise VH and VL
- the VH may comprise the amino acid sequence shown in SEQ ID NO:8
- the VL may comprise the amino acid sequence shown in SEQ ID NO:18 .
- the first antigen-binding protein may comprise a heavy chain and a light chain
- the heavy chain may comprise the amino acid sequence shown in SEQ ID NO: 10
- the light chain may comprise the amino acid sequence shown in SEQ ID NO: 20 The amino acid sequence shown.
- the second antigen-binding protein may comprise at least one CDR in the antibody heavy chain variable region VH, which may comprise the amino acid sequence shown in SEQ ID NO: 27.
- the second antigen-binding protein may comprise HCDR3, and the HCDR3 may comprise the amino acid sequence shown in SEQ ID NO: 21.
- the second antigen-binding protein may comprise HCDR2, and the HCDR2 may comprise the amino acid sequence shown in SEQ ID NO: 22.
- the second antigen-binding protein may comprise HCDR1, and the HCDR1 may comprise the amino acid sequence shown in SEQ ID NO: 23.
- the second antigen-binding protein may comprise HCDR1, HCDR2 and HCDR3, the HCDR1 may comprise the amino acid sequence shown in SEQ ID NO:23, and the HCDR2 may comprise the amino acid sequence shown in SEQ ID NO:22 sequence, and the HCDR3 may comprise the amino acid sequence shown in SEQ ID NO: 21.
- the second antigen-binding protein may comprise H-FR1
- the C-terminus of the H-FR1 is directly or indirectly connected to the N-terminus of the HCDR1
- the H-FR1 may comprise SEQ ID NO: The amino acid sequence shown in 24.
- the second antigen-binding protein may comprise H-FR2, the H-FR2 is located between the HCDR1 and the HCDR2, and the H-FR2 may comprise SEQ ID NO: 25 Amino acid sequence.
- the second antigen-binding protein may comprise H-FR3, the H-FR3 is located between the HCDR2 and the HCDR3, and the H-FR3 may comprise SEQ ID NO: 26 Amino acid sequence.
- the second antigen-binding protein may comprise H-FR4, the N-terminus of the H-FR4 is directly or indirectly connected to the C-terminus of the H-FR3, and the H-FR4 comprises SEQ ID NO. :The amino acid sequence shown in 7.
- the second antigen-binding protein may comprise H-FR1, H-FR2, H-FR3 and H-FR4.
- the H-FR1 includes the amino acid sequence shown in SEQ ID NO:24
- the H-FR2 may include the amino acid sequence shown in SEQ ID NO:25
- the H-FR3 may include the amino acid sequence shown in SEQ ID NO:26.
- the amino acid sequence shown is, and the H-FR4 may comprise the amino acid sequence shown in SEQ ID NO:7.
- the second antigen-binding protein includes VH, and the VH includes the amino acid sequence shown in SEQ ID NO:8.
- the second antigen binding protein may comprise an antibody heavy chain constant region.
- the antibody heavy chain constant region is derived from an IgG heavy chain constant region.
- the antibody heavy chain constant region is derived from a human IgG heavy chain constant region.
- the antibody heavy chain constant region is derived from a human IgG1 heavy chain constant region or a human IgG4 heavy chain constant region.
- the antibody heavy chain constant region includes the amino acid sequence shown in SEQ ID NO: 9.
- the second antigen-binding protein may comprise an antibody heavy chain, and the antibody heavy chain may comprise the amino acid sequence shown in SEQ ID NO: 28.
- the second antigen-binding protein may comprise at least one CDR in the antibody light chain variable region VL, which may comprise the amino acid sequence shown in SEQ ID NO: 35.
- the second antigen-binding protein may comprise LCDR3, and the LCDR3 may comprise the amino acid sequence shown in SEQ ID NO: 29.
- the second antigen-binding protein may comprise LCDR2, and the LCDR2 may comprise the amino acid sequence shown in SEQ ID NO: 30 (LAS).
- the second antigen-binding protein may comprise LCDR1, and the LCDR1 may comprise the amino acid sequence shown in SEQ ID NO: 31.
- the second antigen-binding protein may comprise LCDR1, LCDR2 and LCDR3, the LCDR1 may comprise the amino acid sequence described in SEQ ID NO:31, and the LCDR2 may comprise the amino acid sequence described in SEQ ID NO:30 (LAS) The amino acid sequence shown is, and the LCDR3 may comprise the amino acid sequence shown in SEQ ID NO: 29.
- the second antigen-binding protein may comprise L-FR1
- the C-terminus of the L-FR1 is directly or indirectly connected to the N-terminus of the LCDR1
- the L-FR1 may comprise SEQ ID NO: The amino acid sequence shown in 32.
- the second antigen-binding protein may comprise L-FR2, the L-FR2 is located between the LCDR1 and the LCDR2, and the L-FR2 may comprise SEQ ID NO:33 Amino acid sequence.
- the second antigen-binding protein may comprise L-FR3, the L-FR3 is located between the LCDR2 and the LCDR3, and the L-FR3 comprises the amino acid shown in SEQ ID NO:34 sequence.
- the second antigen-binding protein may comprise L-FR4, the N-terminus of the L-FR4 is directly or indirectly connected to the C-terminus of the L-FR3, and the L-FR4 comprises SEQ ID NO. :The amino acid sequence shown in 17.
- the second antigen binding protein may comprise L-FR1, L-FR2, L-FR3 and L-FR4.
- the L-FR1 may include the amino acid sequence shown in SEQ ID NO:32
- the L-FR2 may include the amino acid sequence shown in SEQ ID NO:33
- the L-FR3 may include SEQ ID NO:34
- the L-FR4 may include the amino acid sequence shown in SEQ ID NO:17.
- the second antigen-binding protein includes VL, and the VL includes the amino acid sequence shown in SEQ ID NO:35.
- the second antigen binding protein may comprise an antibody light chain constant region.
- the antibody light chain constant region may be derived from a human Ig ⁇ constant region.
- the antibody light chain constant region may comprise the amino acid sequence shown in SEQ ID NO: 19.
- the second antigen-binding protein may comprise an antibody light chain, and the antibody light chain may comprise the amino acid sequence shown in SEQ ID NO: 36.
- the second antigen-binding protein may comprise VH and VL
- the VH may comprise the amino acid sequence shown in SEQ ID NO: 27
- the VL may comprise the amino acid sequence shown in SEQ ID NO: 35 .
- the second antigen-binding protein may comprise a heavy chain and a light chain
- the heavy chain may comprise the amino acid sequence shown in SEQ ID NO: 28
- the light chain may comprise the amino acid sequence shown in SEQ ID NO: 36 The amino acid sequence shown.
- the first antigen-binding protein and the second antigen-binding protein in the pharmaceutical combination may be mixed in a certain mass ratio.
- they can be mixed at a mass ratio of about 1:5 to 5:1.
- the mass ratio of the first antigen-binding protein to the second antigen-binding protein is about 1:5.
- the mass ratio of the first antigen-binding protein to the second antigen-binding protein is about 1:2.5.
- the mass ratio of the first antigen-binding protein to the second antigen-binding protein is about 1:1.
- the mass ratio of the first antigen-binding protein to the second antigen-binding protein is about 2.5:1.
- the mass ratio of the first antigen-binding protein to the second antigen-binding protein is about 5:1.
- the pharmaceutical combination may be formulated for administration by intravenous injection.
- the present application also provides a pharmaceutical composition comprising the pharmaceutical combination, and optionally one or more pharmaceutically acceptable carriers.
- the pharmaceutical composition may be a mixture comprising the first antigen-binding protein and the second antigen-binding protein, and the mixture may further comprise inactive ingredients to be formulated as a pharmaceutically acceptable preparation.
- the concentration of the pharmaceutical combination is about 3-300 mg/mL, optionally about 3-150 mg/mL, optionally about 5-100 mg/mL, optionally about 10-100 mg/mL.
- mL optionally about 10-50 mg/mL, for example, about 30 ⁇ 5 mg/mL, for example, about 30 ⁇ 3 mg/mL.
- the pharmaceutical composition may comprise a buffer.
- the buffer may be an acidic buffer.
- the buffer may be a neutral buffer.
- the buffer may be selected from the group consisting of: acetate-acetate buffer, histidine-histidine hydrochloride buffer, citrate-citrate buffer, phosphate buffer, histidine buffer Acid-acetate buffer, Tris-HCl buffer, phosphate-citrate, or combinations thereof.
- the buffer may be selected from the group consisting of acetate-acetic acid, citrate-citrate, histidine-histidine hydrochloride, Phosphate, Tris-hydrochloride, histidine-acetate, phosphate-citrate, or combinations thereof.
- the buffer may be selected from one or more of the following group: sodium acetate-acetic acid, sodium citrate-citric acid, histidine-histidine hydrochloride, sodium dihydrogen phosphate-hydrogen phosphate Disodium, Tris-hydrochloride, histidine-acetate, and phosphate-sodium citrate.
- the buffer may be histidine-acetate buffer.
- the concentration of the buffer may be about 5-100mM, optionally about 5-60mM, optionally about 5-50mM, optionally about 10-40mM, optionally about 20 ⁇ 5mM, optionally about 20 ⁇ 2mM.
- the pH of the pharmaceutical composition may be about 5-7.
- the pharmaceutical composition has a pH of about 6 ⁇ 0.5.
- the pharmaceutical composition has a pH of about 6 ⁇ 0.3.
- the pharmaceutical composition has a pH of about 6 ⁇ 0.1.
- the pharmaceutical composition has a pH of about 6.5 ⁇ 0.3.
- the pharmaceutical composition has a pH of about 7 ⁇ 0.3.
- the pharmaceutical composition may comprise a stabilizer.
- the stabilizer may be selected from the group consisting of sodium chloride, amino acids, sugar alcohols, or combinations thereof.
- the amino acid may be selected from the following group: proline, arginine, glycine, histidine, lysine, methionine Methionine), or combinations thereof.
- the sugar alcohol may be selected from the group consisting of sucrose, mannitol, trehalose, sorbitol, or a combination thereof.
- the stabilizer may be selected from one or more of the following group: sucrose, trehalose, sorbitol, mannitol, proline/sucrose, methionine/trehalose, glycine/mannitol, sodium chloride/ Sucrose, arginine/sucrose, and lysine/trehalose.
- the stabilizer of the pharmaceutical composition may be sucrose.
- the content of the stabilizer in the pharmaceutical composition is about 0.15wt.%-20wt.%, optionally the content of the stabilizer is about 0.15wt.%-10wt.%, optionally the stabilizer is The content is about 0.15wt.%-8wt.%, optionally the content of the stabilizer is about 4 ⁇ 1wt.% or 8 ⁇ 1wt.%, optionally the content of the stabilizer is about 4 ⁇ 0.5wt.%, 8 ⁇ 0.5 wt.%, optionally the stabilizer content is about 4, 5, 7 or 8 wt.%.
- the content of the stabilizer is about 0.15wt.%, about 0.2wt.%, about 0.3wt.%, about 0.4wt.%, 0.5wt.%, about 0.6wt.%, about 0.8wt.%, About 1wt.%, about 1.5wt.%, about 2wt.%, about 2.5wt.%, about 3wt.%, about 3.5wt.%, about 4wt.%, about 4.5wt.%, about 5wt.%, about 5.5wt.%, about 6wt.%, about 7wt.%, about 8wt.%.
- the pharmaceutical composition may comprise a surfactant.
- the surfactant may be selected from the following group: polyoxyethylene sorbitan fatty acid esters, polyoxyethylene hydrogenated castor oil, glycerol fatty acid esters, polysorbates, poloxamer, or their combination.
- the polysorbate may be selected from the following group: polysorbate 20 (PS-20, Tween-20), polysorbate 40 (PS-40), polysorbate 60 (PS-60), polysorbate 80 (PS-80).
- the surfactant may include Tween-20 (PS-20) and/or Tween-80 (PS-80).
- the concentration of the surfactant is about 0.001%-0.5%, optionally about 0.005%-0.1%, optionally about 0.005%, 0.01%, 0.03%, 0.05% or 0.1%, optionally Ground is about 0.01% or 0.03%.
- the concentration of the surfactant is about 0.005%, about 0.01%, 0.03%, about 0.05%, about 0.1%.
- the buffer system of the pharmaceutical composition may include 20mM histidine-acetic acid, 8wt.% sucrose, and 0.03wt.% Tween-80.
- the buffer system of the pharmaceutical composition may include 20mM sodium acetate-acetic acid, 8wt.% trehalose, and 0.03wt.% Tween-80.
- the buffer system of the pharmaceutical composition may include 20mM histidine-acetic acid, 1.5wt.% proline, 5wt.% sucrose, and 0.03wt.% Tween-80.
- the buffer system of the pharmaceutical composition may include 20mM sodium acetate-acetic acid, 0.15wt.% methionine, 8wt.% trehalose, and 0.03wt.% Tween-80.
- the buffer system of the pharmaceutical composition may include 20mM histidine-acetic acid, 8wt.% sucrose, and 0.01wt.% Tween-80.
- the buffer system of the pharmaceutical composition may include 20mM sodium acetate-acetic acid, 8wt.% trehalose, and 0.01wt.% Tween-80.
- the buffer system of the pharmaceutical composition may include 20mM histidine-acetic acid, 1.5wt.% proline, 5wt.% sucrose, and 0.01wt.% Tween-80.
- the buffer system of the pharmaceutical composition may include 20mM sodium acetate-acetic acid, 0.15wt.% methionine, 8wt.% trehalose, and 0.01wt.% Tween-80.
- the application provides said pharmaceutical combination and/or the use of said pharmaceutical composition in the preparation of a medicament for the prevention and/or treatment of diseases and/or disorders.
- the present application also provides a method for preventing and/or treating diseases and/or disorders, which method may include administering the pharmaceutical combination and/or the pharmaceutical composition described in the present application to a subject in need thereof.
- the administration may be carried out in different ways, such as intravenous, intratumoral, intraperitoneal, subcutaneous, intramuscular, topical or intradermal administration.
- the pharmaceutical combination and/or the pharmaceutical composition described in this application can be used to prevent and/or treat diseases and/or conditions.
- the disease and/or disorder may be a disease and/or disorder mediated by abnormal expression of CD73.
- the disease and/or condition may include tumors.
- the tumor may include solid tumors and/or hematological tumors.
- the diseases and/or conditions may include pancreatic cancer, breast cancer, and/or idiopathic pulmonary fibrosis (IPF).
- the breast cancer may include triple negative breast cancer.
- the present application also provides a method for detecting CD73 in a sample, the method comprising administering the pharmaceutical combination and/or the pharmaceutical composition.
- the method for detecting CD73 in a sample may be an in vitro method.
- the method of detecting CD73 in a sample may be for non-therapeutic purposes.
- the method of detecting CD73 in a sample is not a diagnostic method.
- the present application also provides a reagent or kit for detecting CD73 in a sample, which includes the pharmaceutical combination and/or the pharmaceutical composition.
- the present application also provides the pharmaceutical combination and/or the use of the pharmaceutical composition in preparing a kit for detecting the presence and/or content of CD73 in a sample.
- CEX-HPLC Use ProPac TM WCX-10 analytical column (4mm ⁇ 250mm), use Water high performance liquid chromatography instrument (E2695), and refer to the general high performance liquid chromatography method of "Pharmacopoeia of the People's Republic of China” (2015 edition, Part 3) Determine and calculate purity by area normalization method.
- Tm value determination (IF, full-spectrum fluorescence): Use Uncle (Unchained Labs), heat at 0.3°C/min in the range of 25°C to 95°C, and use the full-spectrum fluorescence module to calculate the dissolution temperature Tm of different recipes.
- Tagg value determination SLS, static light scattering: Use Uncle instrument to heat at 25°C to 95°C at 0.3°C/minute, and use the static light scattering module to calculate the initial aggregation temperature Tagg of antibody molecules with different prescriptions.
- 900698 (the heavy chain sequence is shown in SEQ ID NO: 10 and the light chain sequence is shown in SEQ ID NO: 20) and 900725 (heavy chain sequence is shown in SEQ ID NO: 28, light chain sequence is shown in SEQ ID NO: 36) diluted to 30ug/ml with PBS, and then according to 1:5, 1:2.5, 1:1, 2.5: Mix 1, 5:1 and dilute 5 times into 8 gradients.
- Residual CD73 activity was: (CHOK1-huCD73-3F4 cells+Ab+ATP+AMP)-(ATP+AMP)/(CHOK1-huCD73-3F4 cells+ATP+AMP) -(ATP+AMP)*100.
- NPG mice were used to establish the BxPC-3 pancreatic cancer animal model and test the efficacy of the tested antibodies.
- the human pancreatic cancer cells BxPC-3 used in this experiment were cultured in RPMI-1640 medium supplemented with 10% FBS in a 37°C incubator containing 5% CO2. Before the cells were continuously cultured for ten generations, 100 ⁇ L of PBS containing approximately 1 ⁇ 107 BxPC-3 cells and an equal volume of Matrigel were mixed and then inoculated subcutaneously into the right side of the back of 36 NPG mice near the armpit, with an inoculation volume of approximately 200 ⁇ L. Mice were anesthetized with 2-5% isoflurane before inoculation.
- 900201 is a negative control antibody that does not bind to the CD73 antigen.
- the heavy chain (HC) amino acid sequence of 900201 is shown in SEQ ID NO:37
- the light chain (LC) amino acid sequence of 900201 is shown in SEQ ID NO:38.
- Oleclumab is an anti-CD73 monoclonal antibody developed by AstraZeneca and is currently in Phase 3 clinical trials.
- Uliledlimab is an anti-CD73 monoclonal antibody developed by I-Mab and is currently in clinical phase 1.
- the results are shown in Table 2 and Figure 3 below.
- the positive drugs oleclumab, uliledlimab, the test drugs 900698, 900725, and the anti-CD73 cocktail antibody can significantly inhibit the growth of BxPC-3 pancreatic cancer, and the same dose
- the anti-CD73 cocktail antibody has a better tumor inhibition effect than the positive controls oleclumab, uliledlimab, and 900698 and 900725, proving that the anti-CD73 antibody cocktail antibody mixed in equal proportions of 900698 and 900725 has a very good synergistic anti-pancreatic cancer tumor effect.
- NPG mice were used to establish the MDA-MB-231 triple-negative breast cancer animal model and test the efficacy of the tested antibodies.
- the human breast cancer cells MDA-MB-231 used in this experiment were cultured in L-15 medium supplemented with 10% FBS in a CO2-free 37°C incubator. Before the cells were continuously cultured for ten generations, approximately 5.0X10 6 MDA-MB-231 cells were suspended in 100 ⁇ L PBS, mixed with an equal volume of Matrigel, and then inoculated into the right side of the back of NPG humanized mice near the armpit by subcutaneous injection. , the inoculation volume is about 200 ⁇ L. Mice were anesthetized with 2-5% isoflurane before inoculation.
- 900201 is a negative control antibody that does not bind to the CD73 antigen.
- Oleclumab is an anti-CD73 monoclonal antibody developed by AstraZeneca and is currently in Phase 3 clinical trials.
- the results are shown in Table 3 and Figure 4 below.
- the positive drug oleclumab, the test drugs 900698, 900725, and the anti-CD73 cocktail antibody can significantly inhibit the growth of MDA-MB-231 triple-negative breast cancer, and are equally effective.
- the tumor inhibitory effect of a dose of anti-CD73 cocktail antibody is better than that of the positive control oleclumab and 900698 and 900725, proving that the anti-CD73 antibody cocktail antibody mixed in equal proportions of 900698 and 900725 has a very good synergistic effect against triple-negative breast cancer tumors.
- Example 5 Therapeutic effect of anti-CD73 cocktail antibody in animal model of idiopathic pulmonary fibrosis (IPF)
- Idiopathic pulmonary fibrosis is a fatal disease characterized by progressive and irreversible pulmonary fibrosis for which there is currently no effective treatment. Most patients die from progressive respiratory failure within 3-8 years after the onset of symptoms. Although the pathogenesis of IPF is poorly understood, hallmark pathological features include inflammatory changes in the lungs, excessive proliferation of fibroblasts, and abnormal deposition of extracellular matrix (ECM). Bleomycin (BLM)-induced fibrosis is widely used to study the pathogenesis of idiopathic pulmonary fibrosis.
- the specific operations of the bleomycin-induced idiopathic pulmonary fibrosis model in CD73 humanized transgenic mice are as follows:
- the CD73 humanized mice are grouped according to the following table 4, that is, except for the 3 randomly selected animals, they are directly included Except for the G1 normal group, animals in all other groups received tracheal infusion of bleomycin for model induction.
- the specific induction method is: on the first day, the animal is anesthetized by inhaling 2-5% isoflurane. Based on body weight, the animal will be given bleomycin (2U/kg) through the intratracheal route. The specific administration volume will be based on Animal body weight was calculated and recorded).
- IPF Idiopathic pulmonary fibrosis
- Airway hyperresponsiveness was measured in experimental mice using the WBP system.
- mice inhaled PBS solution by atomization, and then continuously inhaled methacholine (Mch) at concentrations of 1.5625, 3.125, 6.25, 12.5, 25 and 50 mg/mL, and measured the enhanced expiratory interval value at the corresponding concentration.
- Mch methacholine
- Penh stimulate for 90 seconds at each concentration, draw the change rate of Penh relative to the baseline-Mch concentration curve, and calculate the area under the curve.
- the cell count results of the lung lavage fluid showed that the total number of inflammation-related cells in the alveolar lavage fluid of the animals in the model group was lower than that of the normal group.
- the percentage of lymphocytes increased significantly; after administration of positive drugs and different concentrations of anti-CD73 cocktail antibody test substances, the total inflammation-related cell number and lymphocyte number levels significantly decreased, indicating that anti-CD73 cocktail antibodies can significantly improve idiopathic The degree of inflammation in pulmonary fibrosis.
- the left lung was collected, fixed in neutral formalin and embedded in a wax block, cross-sectioned, and sections were taken from the upper, middle and lower segments, a total of 3 slices/lobe, embedded in a wax block, stained with Masson, and Score the degree of pathological fibrosis. The scoring criteria are shown in Table 5 below.
- histidine-acetic acid (pH 6) will be selected as a buffer to screen other excipients.
- the newly prepared samples were placed under various pressurized conditions, including: high temperature test (40°C ⁇ 2°C, placed for three weeks), repeated freezing and thawing (5 cycles, ⁇ -70°C/5°C ⁇ 3°C). Its stability was evaluated through test items such as appearance and purity. Some test results are shown in Table 10 and Table 11 below.
- sucrose will be used as a stabilizer to conduct surfactant screening experiments.
- the newly prepared samples were placed under various shaking and pressurizing conditions and shaken at room temperature for 3 days (200 rpm).
- the surfactants Tween-20 (PS-20) and Tween-80 (PS-80) were evaluated through appearance and the number of insoluble particles.
- the protective effect is as follows. Some test results are shown in Table 12 below.
- the buffer systems are as follows:
- Example 10 examines the stability of several groups of buffer system anti-CD73 cocktail antibody pharmaceutical preparations prepared in Example 9.
- the stability examination includes pressurization, acceleration and long-term stability examination, as follows:
- Pressurization conditions include: high temperature for 3 weeks (40°C ⁇ 2°C), room temperature shaking for 3 days (60rmp), repeated freezing and thawing (5 cycles, ⁇ -70°C/5°C ⁇ 3°C freezing and thawing), etc.
- T0 control is the control when preparation preparation is completed.
- T0 control is the control when preparation preparation is completed.
- T0 control is the control when preparation preparation is completed.
- the anti-CD73 cocktail antibody pharmaceutical preparations of several groups of buffer systems prepared in Example 9 have good stability, and the anti-CD73 cocktail antibody maintains good stability under various pressure conditions (high temperature, repeated freezing and thawing, and shaking).
- Stability It can be stored stably for at least three months under accelerated conditions (25°C ⁇ 2°C). At the same time, it shows high stability and can be stored stably under long-term refrigeration conditions.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Inorganic Chemistry (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
Priority Applications (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CA3258260A CA3258260A1 (en) | 2022-06-08 | 2023-06-07 | CD73 ANTIBODY COCKTAIL THERAPY |
| JP2024572421A JP2025521231A (ja) | 2022-06-08 | 2023-06-07 | Cd73抗体カクテル療法 |
| US18/872,421 US20260217849A1 (en) | 2022-06-08 | 2023-06-07 | Cd73 antibody cocktail therapy |
| CN202380045319.3A CN119403832A (zh) | 2022-06-08 | 2023-06-07 | Cd73抗体鸡尾酒疗法 |
| KR1020257000422A KR20250023471A (ko) | 2022-06-08 | 2023-06-07 | Cd73 항체 칵테일 요법 |
| EP23819136.5A EP4538289A4 (en) | 2022-06-08 | 2023-06-07 | CD73 ANTIBODY COCKTAIL THERAPY |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210639331.4 | 2022-06-08 | ||
| CN202210639331 | 2022-06-08 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2023236971A1 true WO2023236971A1 (zh) | 2023-12-14 |
Family
ID=89117604
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/CN2023/098753 Ceased WO2023236971A1 (zh) | 2022-06-08 | 2023-06-07 | Cd73抗体鸡尾酒疗法 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20260217849A1 (cg-RX-API-DMAC10.html) |
| EP (1) | EP4538289A4 (cg-RX-API-DMAC10.html) |
| JP (1) | JP2025521231A (cg-RX-API-DMAC10.html) |
| KR (1) | KR20250023471A (cg-RX-API-DMAC10.html) |
| CN (1) | CN119403832A (cg-RX-API-DMAC10.html) |
| CA (1) | CA3258260A1 (cg-RX-API-DMAC10.html) |
| TW (1) | TW202405018A (cg-RX-API-DMAC10.html) |
| WO (1) | WO2023236971A1 (cg-RX-API-DMAC10.html) |
Citations (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US6420140B1 (en) | 1996-10-11 | 2002-07-16 | Abgenix, Inc. | Production of multimeric protein by cell fusion method |
| US6458592B1 (en) | 1995-03-29 | 2002-10-01 | Abgenix, Inc. | Production of antibodies using cre-mediated site-specific recombination |
| WO2006003388A2 (en) | 2004-06-30 | 2006-01-12 | Domantis Limited | Compositions and methods for treating inflammatory disorders |
| WO2006030220A1 (en) | 2004-09-17 | 2006-03-23 | Domantis Limited | Compositions monovalent for cd40l binding and methods of use |
| WO2017118613A1 (en) * | 2016-01-08 | 2017-07-13 | Syddansk Universitet | Bispecific antibodies targeting human cd73 |
| WO2021097223A2 (en) * | 2019-11-15 | 2021-05-20 | Genzyme Corporation | Biparatopic cd73 antibodies |
| WO2022122004A1 (zh) * | 2020-12-11 | 2022-06-16 | 上海华奥泰生物药业股份有限公司 | Cd73的抗原结合蛋白及其应用 |
| WO2022152144A1 (zh) * | 2021-01-13 | 2022-07-21 | 上海华奥泰生物药业股份有限公司 | 结合cd73的蛋白及其应用 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2017228470A1 (en) * | 2016-03-04 | 2018-08-30 | Bristol-Myers Squibb Company | Combination therapy with anti-CD73 antibodies |
| JP2023546743A (ja) * | 2020-10-23 | 2023-11-07 | 中山康方生物医▲藥▼有限公司 | 抗cd73抗体及びその使用 |
-
2023
- 2023-06-07 WO PCT/CN2023/098753 patent/WO2023236971A1/zh not_active Ceased
- 2023-06-07 EP EP23819136.5A patent/EP4538289A4/en active Pending
- 2023-06-07 US US18/872,421 patent/US20260217849A1/en active Pending
- 2023-06-07 KR KR1020257000422A patent/KR20250023471A/ko active Pending
- 2023-06-07 CA CA3258260A patent/CA3258260A1/en active Pending
- 2023-06-07 TW TW112121274A patent/TW202405018A/zh unknown
- 2023-06-07 CN CN202380045319.3A patent/CN119403832A/zh active Pending
- 2023-06-07 JP JP2024572421A patent/JP2025521231A/ja active Pending
Patent Citations (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US6458592B1 (en) | 1995-03-29 | 2002-10-01 | Abgenix, Inc. | Production of antibodies using cre-mediated site-specific recombination |
| US6420140B1 (en) | 1996-10-11 | 2002-07-16 | Abgenix, Inc. | Production of multimeric protein by cell fusion method |
| WO2006003388A2 (en) | 2004-06-30 | 2006-01-12 | Domantis Limited | Compositions and methods for treating inflammatory disorders |
| WO2006030220A1 (en) | 2004-09-17 | 2006-03-23 | Domantis Limited | Compositions monovalent for cd40l binding and methods of use |
| WO2017118613A1 (en) * | 2016-01-08 | 2017-07-13 | Syddansk Universitet | Bispecific antibodies targeting human cd73 |
| WO2021097223A2 (en) * | 2019-11-15 | 2021-05-20 | Genzyme Corporation | Biparatopic cd73 antibodies |
| WO2022122004A1 (zh) * | 2020-12-11 | 2022-06-16 | 上海华奥泰生物药业股份有限公司 | Cd73的抗原结合蛋白及其应用 |
| WO2022152144A1 (zh) * | 2021-01-13 | 2022-07-21 | 上海华奥泰生物药业股份有限公司 | 结合cd73的蛋白及其应用 |
Non-Patent Citations (16)
| Title |
|---|
| "Basic and Clinical Immunology", 1994, APPLETON & LANGE, pages: 71 |
| "General Chapter 0514 in the Pharmacopoeia of the People s Republic of China", vol. 3, 2015 |
| "Uniprot", Database accession no. P21589 |
| D. J. LIPMANW. R. PEARSON: "Rapid and Sensitive Protein Similarity Searches", SCIENCE, vol. 227, 1989, pages 1435 - 1441 |
| GAMMELGAARD ODD L, TERP MIKKEL G, RENN CHRISTIAN, LABRIJN ARAN F, HAMAKER OLIVER, NIELSEN AARABY Y, VEVER HENRIETTE, HANSEN SOREN : "Targeting two distinct epitopes on human CD73 with a bispecific antibody improves anticancer activity", JOURNAL FOR IMMUNOTHERAPY OF CANCER, BIOMED CENTRAL, LONDON, GB, vol. 10, no. 9, 1 September 2022 (2022-09-01), GB , pages e004554, XP093113664, ISSN: 2051-1426, DOI: 10.1136/jitc-2022-004554 * |
| HAMERS-CASTERMAN ET AL., NATURE, vol. 363, 1993, pages 446 - 448 |
| HOLT ET AL., TRENDS BIOTECHNOL., vol. 21, no. 11, 2003, pages 484 - 490 |
| JAMES E STEFANO, DANA M LORD, YANFENG ZHOU, JULIE JAWORSKI, JOERN HOPKE, TARA TRAVALINE, NINGNING ZHANG, KAREN WONG, AMANDA LENNON: "A highly potent CD73 biparatopic antibody blocks organization of the enzyme active site through dual mechanisms", JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY FOR BIOCHEMISTRY AND MOLECULAR BIOLOGY, US, US , pages jbc.RA120.012395, XP055749199, ISSN: 0021-9258, DOI: 10.1074/jbc.RA120.012395 * |
| KABAT ET AL.: "Sequences of Immunological Interest", 1991, NATIONAL INSTITUTE OF HEALTH |
| KORNDORFER ET AL., PROTEINS: STRUCTURE, FUNCTION, AND BIOINFORMATICS, vol. 53, no. 1, 2003, pages 121 - 129 |
| ROQUE ET AL., BIOTECHNOL. PROG., vol. 20, 2004, pages 639 - 654 |
| S. ALTSCHULW. GISHW. MILLERE. W. MYERSD. LIPMAN: "A Basic Local Alignment Search Tool", JOURNAL OF MOLECULAR BIOLOGY, vol. 215, 1990, pages 403 - 410 |
| See also references of EP4538289A4 |
| SHERIFF ET AL., NATURE STRUCT. BIOL., vol. 3, 1996, pages 733 - 736 |
| W. R. PEARSOND. J. LIPMAN: "Improved Tools for Biological Sequence Comparison", PROC. NATL. ACAD. SCI., vol. 85, 1988, pages 2444 - 2448 |
| WARD ET AL., NATURE, vol. 341, no. 6242, 12 October 1989 (1989-10-12), pages 544 - 6 |
Also Published As
| Publication number | Publication date |
|---|---|
| JP2025521231A (ja) | 2025-07-08 |
| US20260217849A1 (en) | 2026-07-30 |
| CA3258260A1 (en) | 2025-03-18 |
| TW202405018A (zh) | 2024-02-01 |
| EP4538289A1 (en) | 2025-04-16 |
| EP4538289A4 (en) | 2026-06-17 |
| KR20250023471A (ko) | 2025-02-18 |
| CN119403832A (zh) | 2025-02-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6007316B2 (ja) | 抗体製剤 | |
| TWI761869B (zh) | 包含抗cd47/pd-l1雙特異性抗體的製劑及其製備方法和用途 | |
| US20210269540A1 (en) | Antibody formulation | |
| AU2020285636A1 (en) | IL-2 compositions and methods of use thereof | |
| CN108348581B (zh) | 胰岛素免疫球蛋白融合蛋白 | |
| AU2020315282A1 (en) | IL-2 compositions and methods of use thereof | |
| TW200944245A (en) | Powdered protein compositions and methods of making same | |
| KR20190008320A (ko) | 약학 조성물 | |
| KR20120130752A (ko) | 혈관신생-관련된 안질환의 치료를 위한 조성물 및 방법 | |
| US20190023792A1 (en) | Pd-1 antibodies | |
| CN118591564A (zh) | 一种双特异性抗原结合分子及其应用 | |
| KR20210153039A (ko) | 커넥신 43 항체 및 이의 용도 | |
| EP4248995A1 (en) | Use of anti-ox40 antibody for treating tumors or cancers | |
| CN111201036A (zh) | 包含抗α(V)β(6)抗体的药物组合物和剂量方案 | |
| US20240182537A1 (en) | Il-15 procytokine antibody fusion proteins | |
| KR20210097750A (ko) | Cd40 항체 약학 조성물 및 이의 용도 | |
| EP4538289A1 (en) | Cd73 antibody cocktail therapy | |
| CN118812720A (zh) | 靶向pdl1和cd3的双特异性抗体及其应用 | |
| CN118576543A (zh) | 一种结合人CD3/IL13Rα的双特异性抗体制剂及其应用 | |
| JP2022176154A (ja) | ムコ多糖症i型の治療用医薬組成物 | |
| EA053234B1 (ru) | Терапия коктейлем антител против cd73 | |
| EP4501313A1 (en) | Preparations containing anti-claudin18.2/cd3 bispecific antibody, preparation method therefor and use thereof | |
| CN114149508B (zh) | 一种结合cd40l的融合蛋白及其应用 | |
| US20240092914A1 (en) | Depletion and inhibition of plasmacytoid dendritic cells | |
| TW202409092A (zh) | Cd39/cd73雙特異性抗原結合蛋白及其用途 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 23819136 Country of ref document: EP Kind code of ref document: A1 |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 2024572421 Country of ref document: JP Ref document number: 202380045319.3 Country of ref document: CN |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 202493155 Country of ref document: EA |
|
| ENP | Entry into the national phase |
Ref document number: 20257000422 Country of ref document: KR Kind code of ref document: A |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 1020257000422 Country of ref document: KR |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 2023819136 Country of ref document: EP |
|
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| ENP | Entry into the national phase |
Ref document number: 2023819136 Country of ref document: EP Effective date: 20250108 |
|
| WWP | Wipo information: published in national office |
Ref document number: 202380045319.3 Country of ref document: CN |
|
| WWP | Wipo information: published in national office |
Ref document number: 1020257000422 Country of ref document: KR |
|
| WWP | Wipo information: published in national office |
Ref document number: 2023819136 Country of ref document: EP |